================================================================================
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 4, 2007
ONCOLOGIX TECH, INC.
---------------------------------------------------------
(Name of Small Business Issuer as Specified in Its Charter)
0-15482
----------------------
(Commission File Number)
Nevada 86-1006416
------------------------------ -----------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
3725 Lawrenceville-Suwanee Rd., Suite B-4
Suwanee, GA 30024
--------------------------------------
(Address of principal executive offices)
(770) 831-8818
------------------------
(Issuer's telephone number)
Check the appropriate box below if the Form 8-K is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
================================================================================
Item 8.01 Other Events.
Mr. Stanley L. Schloz, a director and our Chairman, agreed to advance
$150,000 to the Company pursuant to a convertible promissory note, to be dated
September 4, 2007, in that principal amount, to accrue interest at the rate of
1% per month, to be paid monthly. The principal and accrued interest under the
promissory note is convertible into our common stock at the rate of $0.20 per
share. In addition, Mr. Anthony Silverman, another of our directors, agreed to
extend payment on aggregate principal indebtedness of approximately $880,450 to
December 15, 2007. The $880,450 in aggregate principal consists of a $200,000
promissory note, a $400,000 promissory note, an $80,450 convertible promissory
note and a $200,000 convertible promissory note.
Mountainview Opportunistic Growth Fund, L.P., an Ontario limited
partnership, agreed to extend repayment under our $350,000 promissory note until
January 15, 2008, and in consideration of that extension, we have decreased the
per share stock conversion price under that promissory note from $1.00 to $0.20.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
Dated: September 7, 2007 ONCOLOGIX TECH INC.
By: /s/ Andrew M. Green
----------------------------------
Andrew M. Green,
Chief Executive Officer and
President
By: /s/ Michael A. Kramarz
----------------------------------
Michael A. Kramarz,
Chief Financial Officer